Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.